Insulet Corporation Stock News

Insulet Corp said on Tuesday Wayde McMillan would step down as the medical device maker's chief financial officer, effective Oct. 20, to join 3M's healthcare business.

Matt Taylor, Jefferies analyst, and Dan Dolev, managing director at Mizuho Securities, join 'The Exchange' to discuss how new weight loss drugs could decline revenue for restaurant transaction platfor

SolarEdge Technologies Inc. (SEDG), Insulet Corp. (PODD), and Dollar General Corp. (DG) were the steepest S&P 500 stock decliners in the third quarter as the index lost 3.65%.

Wall Street says insulin pump maker Insulet and Tandem Diabetes, as well as glucose-monitor maker DexCom, look ready to rise after pressure from Novo Nordisk's Wegovy and Eli Lilly.

The shares of Insulet Corporation (NASDAQ:PODD) are higher before this morning's open, after Jefferies upgraded the medical equipment distributor to "buy" from "hold," with a price-target cut to $240

Insulet Corp. shares PODD, -2.67% gained 4% premarket on Monday after Jefferies analysts upgraded the stock to buy from hold, saying its valuation looks attractive after the shares were dragged down b

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced

Returning to the pre-inflation shock level of $318 means that PODD stock will have to gain more than 100% from here.

Outside of a handful of highflying technology stocks, U.S. stocks have been practically flat in 2023, but on Wall Street, some analysts remain as bullish as ever.

Citi has released a list of 20 large-cap growth stocks that it says present opportunities in the event of a pullback.

With markets remaining choppy and sentiment still cautious, many quality stocks are trading at tempting valuations. Recent indiscriminate selling has knocked down the valuations of profitable, growing

Investors continue to be optimistic about Insulet (PODD) on the strength of the Omnipod 5 AID system.

Insulet's (PODD) international expansion efforts are aligned with its long-term growth profile.

Insulet's CEO stated today that new diabetes drugs could impact how quickly patients begin insulin therapy. However, the company doesn't expect any long-term impact on sales of its insulin pumps.